Full Document

FormatFile SizeNotes
PDF file 4.7 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.


Purchase Print Copy

 FormatList Price Price
Add to Cart Paperback134 pages $30.00 $24.00 20% Web Discount

The research reported is the most thorough investigation to date on the effect of patient package inserts (PPIs). It represents a prospective study of the effects of various prototype PPIs on actual drug users. Drug information documents can vary radically in format, length, content, and style. To determine what type of document works best, it is desirable to conduct experiments that systematically vary such factors as the content, style, and format of the document while controlling for other factors. The research in this report applies such a strategy to study alternative leaflets for flurazepam hydrochloride (Dalmane), a hypnotic drug (sleeping capsule). The results of two studies for this drug are presented, investigating the effects of four different structural variables: specificity of instructions, amount of explanation, writing style, and risk emphasis. Also examined are the effects of receiving any PPI vs. receiving none.

This report is part of the RAND Corporation Report series. The report was a product of the RAND Corporation from 1948 to 1993 that represented the principal publication documenting and transmitting RAND's major research findings and final research.

Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.